Rezolute, Inc. (RZLT) is a late-stage rare-disease biopharmaceutical company developing ersodetug, an investigational antibody designed to treat hypoglycemia caused by hyperinsulinism. It is a stock, not an ETF. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Nine current, individually attributed analyst price targets were reviewed for this analysis: Maxim Group ($14), Citizens JMP ($15), Lake Street ($12), Guggenheim ($11), H.C. Wainwright ($10), Wedbush ($6), BTIG ($6), Craig-Hallum ($7), and JonesTrading ($6). An older Jefferies target of $20, published in December 2025, sits outside the current range and was treated as stale. The nine targets produce an arithmetic mean of roughly $9.70, which rounds to the $10 central target used throughout this article. The approximate range runs from $6 to $15.
The analyst consensus skews strongly bullish — all nine targets carry Buy or Outperform ratings — yet the dispersion is unusually wide. Lower targets near $6 reflect skepticism about the congenital hyperinsulinism (cHI) program, while targets of $12 to $15 emphasize the positive tumor hyperinsulinism (tHI) data and a potentially expanded approval opportunity. Notable recent actions include upgrades at Craig-Hallum (to Buy) and Citizens JMP (to Outperform), plus target increases at Lake Street and Citizens JMP.
Rezolute shares closed near $3.58 in mid-November 2026, leaving a required upside of approximately 179% to reach the $10 average analyst price target. By any standard, that is a very large move — consistent with a clinical-stage biotech whose valuation hinges on regulatory outcomes rather than current earnings, given the company remains unprofitable with no approved products.
The path to $10 would most plausibly run through the tHI program. Rezolute's Phase 3 upLIFT study met its primary endpoint, with 13 of 16 enrolled patients achieving the responder criterion and 12 discontinuing intravenous glucose entirely. Topline results are expected by mid-December 2026. If the final readout is clean and the FDA accepts a Biologics License Application (BLA) filing, investors could begin pricing a commercial opportunity in tHI. Meanwhile, the agency has recommended a pre-BLA meeting for ersodetug in cHI, offering a possible second regulatory path despite the sunRIZE trial's missed primary endpoint.
Rezolute's 52-week range spans roughly $1.07 to $11.46, underscoring the stock's extreme volatility. The $10 central target sits just below the 52-week high, meaning the shares have already traded at levels near the average analyst price target during 2026 before pulling back. Following the tHI data, the stock surged roughly 38% in a week before retreating toward $3.58 amid the equity offering, highlighting how quickly sentiment can shift in a small-cap biotech.
Analyst price targets typically reflect a research horizon of about 12 months, though individual analysts may use different periods. The most important near-term catalyst is the final upLIFT topline data expected by mid-December 2026, followed by any FDA feedback on the cHI pre-BLA meeting and potential BLA submissions. Investors should also track quarterly earnings updates for cash position and dilution, analyst target revisions, and any new safety or efficacy data from the ongoing open-label extension studies.
From what I see, tools like Tickeron’s AI Trend Prediction Engine can help flag shifts in sentiment around names like this one before they fully play out in the broader market. I’m watching this closely as the December data readout approaches.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
On November 18, 2026, the Stochastic Oscillator for RZLT moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 59 instances where the indicator left the oversold zone. In 55 of the 59 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.
The Momentum Indicator moved above the 0 level on November 17, 2026. You may want to consider a long position or call options on RZLT as a result. In 90 of 100 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for RZLT just turned positive on November 17, 2026. Looking at past instances where RZLT's MACD turned positive, the stock continued to rise in 48 of 50 cases over the following month. The odds of a continued upward trend are 90%.
RZLT moved above its 50-day moving average on November 18, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +18.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where RZLT advanced for three days, in 242 of 267 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RZLT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for RZLT entered a downward trend on November 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 29 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.727) is normal, around the industry mean (3.592). P/E Ratio (-5.173) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. RZLT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RZLT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology